Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis

Journal of Rheumatology

Volumn 36, Issue 3, 2009, Pages 491-500

  Mutlu, Nilgun ^a   Bicakcigil, Muge ^a   Tasan, Demet A ^b   Kaya, Ayhan ^b   Yavuz, Sule ^c   Ozden, A Inci ^a  

^a YEDITEPE UNIVERSITY   (Turkey)

^b DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

Automation; Cyclic citrullinated peptide autoantibodies; Diagnosis; Differentiation; Early rheumatoid arthritis; Mutated citrullinated vimentin

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; MUTATED CITRULLINATED VIMENTIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 65649151408     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080656     Document Type: Article

References (39)

1. MacGregor AJ, Silman AJ. Rheumatoid arthritis - classification and epidemiology. In: Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby; 2000:5.2.1-6.
2. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-285
3. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease modifying antirheumatic drugs. Arthritis Rheum 2004;50:2072-2081
4. Mottonen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988;47:648-653 (Pubitemid 18206273)
5. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl:1-8. (Pubitemid 26013493)
6. Moreland LW, Bridges SL. Early rheumatoid arthritis: a medical emergency? Am J Med 2001;111:498-500.
7. Saraux A, Berthelot JM, Chales G, et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 2001;44:2485-2491
8. Harrison BJ, Symmons DP, Barrett EM, Silman AJ. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol 1998;25:2324-2330
9. Hulsemann JL, Zeidler H. Diagnostic evaluation of classification criteria for rheumatoid arthritis and reactive arthritis in an early synovitis outpatient clinic. Ann Rheum Dis 1999;58:278-280 (Pubitemid 29232138)
10. Taylor HG, Dawes PT. The utility of the 1987 revised ARA criteria for rheumatoid arthritis in early synovitis. Br J Rheumatol 1991;30:319.
11. Visser H, Cessie SL, Vos K, Breedveld F, Hazes J. How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-365 (Pubitemid 34136572)
12. Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K. Citrullination of fibronectin in synovial tissue of rheumatoid arthritis. Rheumatology Oxford 2005;44:1374-1382 (Pubitemid 41631860)
13. Vossenaar ER, van Venrooij WJ. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 2006;6:107-111
14. Raptopoulou A, Sidiropoulos P, Katsouraki M, Boumpas DT. Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts. Crit Rev Clin Lab Sci 2007;44:339-363 (Pubitemid 46897707)
15. Yamada R, Suzuki A, Chang X, Yamamoto K. Citrullinated proteins in rheumatoid arthritis. Front Biosci 2005;10:54-64. (Pubitemid 40543017)
16. Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004;4:239-262 (Pubitemid 38495780)
17. van Gaalen FA, Visser H, Huizinga TWJ. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 2005;64:1510-1512 (Pubitemid 41623868)
18. van Venrooij WJ, Zendman AJW, Pruijn GJM. Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 2006;6:37-41. (Pubitemid 44716772)
19. Lutteri L, Malaise M, Chapelle JP. Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 2007;386:76-81. (Pubitemid 47417966)
20. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006;8:1-6.
21. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-2511 (Pubitemid 47237269)
22. Soos L, Szekanecz Z, Szabó Z, et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 2007;34:1658-1663 (Pubitemid 47267606)
23. Mathsson L, Mullazehi M, Wick MC, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis. Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008;58:36-45.
24. Liao KP, Batra KL, Chibnik L, Schur PH, Costenbader KH. Anti-CCP revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis 2008;67:1557-1561 Epub 2008 Jan 30.
25. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
26. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
27. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-1049
28. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicenter study. The European Study Group on Diagnostic Criteria for Sjogren's syndrome. Ann Rheum Dis 1996;55:116-121 (Pubitemid 126422962)
29. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-568 (Pubitemid 23118304)
30. Bizzaro N, Tonutti E, Tozzoli R, Villalta D. Analytical and diagnostics characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007;53:1527-1533 (Pubitemid 47206351)
31. Gottenberg JE, Mignot S, Nicaise-Rolland P, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis 2005;64:114-117 (Pubitemid 40075286)
32. Chan MT, Owen P, Dunphy J, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC class II alleles in systematic lupus erythematosus. J Rheumatol 2008;35:77-83.
33. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008;35:1002-1008
34. Ursum J, Nielen M, Schaardenburg D, et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008;10/R12:1-6.
35. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.
36. Luis Caro-Oleas J, Fernandez-Suarez A, Reneses Cestores S, Porrino C, Nunez-Roldan A, Wichmann Schlipf I. Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent onset polyarthritis. Clin Chem Lab Med 2007;45:1396-1401 (Pubitemid 47557085)
37. Santiago M, Baron M, Miyachi K, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008;27:77-83. (Pubitemid 350182681)
38. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007;53:1-7. (Pubitemid 46447947)
39. Herold M, Boeser V, Russe E, Klotz W. Anti-CCP: history and its usefulness. Clin Dev Immunol 2005;12:131-135